Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Braxia Scientific Corp C.BRAX

Alternate Symbol(s):  BRAXF

Braxia Scientific Corp. is a Canada-based company, which is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing drugs and delivery methods. The Company seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The Company has clinic operations in the Canadian cities of Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. The Company, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., it operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal. Its subsidiaries include Altmed Capital Corp., Artisan Growers Ltd., KetaMD, Inc., Novo Formulations Ltd. and Tassili Life Sciences Corp.


CSE:BRAX - Post by User

Post by Greensavageon Jan 06, 2022 10:55pm
198 Views
Post# 34291618

News

News
BRAXIA SCIENTIFIC ANNOUNCES CAD$3 MILLION PRIVATE PLACEMENT WITH INSTITUTIONAL INVESTORS Braxia Scientific Corp. has entered into a securities purchase agreement with institutional investors for a private placement of its common shares and warrants to purchase common shares for gross proceeds of approximately $3-million. Pursuant to the private placement, the company will issue 30 million common shares (or common share equivalents) and warrants to purchase up to an aggregate of 30 million common shares at a purchase price of 10 cents per common share and associated warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of 12.5 cents for a period of five years following the issuance date. H.C. Wainwright & Co. is acting as the exclusive placement agent for the private placement. The net proceeds of the private placement will be used by the company for the expansion of clinics, certain strategic investments and general working capital purposes. No securities will be offered or sold to Canadian residents in connection with the private placement. The private placement is expected to close on or about Jan. 10, 2022, subject to the satisfaction of customary closing conditions.
<< Previous
Bullboard Posts
Next >>
USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse